Novel China tech attracts SciClone to CHF deal
This article was originally published in Scrip
Executive Summary
US-based but China-focused SciClone Pharmaceuticals has acquired commercial rights to a novel biologic therapy for chronic heart failure (CHF) being developed by Zensun (Shanghai) Science & Technology, marking an interesting acquisition of innovative Chinese technology by a Western firm.